Biogen and Stoke Therapeutics have entered into a collaboration to develop and commercialize Zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome, a severe genetic epileptic encephalopathy characterized by recurrent seizures, cognitive impairments, and behavioral challenges. The agreement grants Biogen commercialization rights outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the primary cause of most Dravet syndrome cases. Stoke plans to initiate a global Phase 3 registrational study in the second quarter of 2025, with pivotal data expected in the second half of 2027 to support regulatory filings.
The collaboration leverages Biogen’s experience in neurology and rare diseases, combined with Stoke’s RNA-based technology. Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics said, “This collaboration provides cash flows, that when combined with Stoke’s financial position, support the company through to mid-2028.” The partnership aims to address the significant unmet needs of patients with Dravet syndrome by offering a potential disease-modifying therapy. Stoke's operations are sustained by the financial provisions of the agreement until mid-2028, which reinforces both companies' dedication to the development of innovative treatments.
